Edoxaban is the most recently approved factor Xa inhibitor within the class of direct oral
anticoagulants (DOACs). Like other DOACs, edoxaban was approved by the US Food and
Drug Administration for treatment of venous thromboembolism and prevention of stroke in
patients with nonvalvular atrial fibrillation. Similar to other DOACs, edoxaban has fewer drug–
drug interactions than warfarin and does not require routine laboratory monitoring. Unlike
other DOACs, edoxaban has yet to be approved for secondary or postoperative venous …